

AMENDMENTS TO THE CLAIMS

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

1-24. (Cancelled)

25. (Currently amended) A method for adjunctively treating major depressive disorder ~~a mood disorder in an individual in need thereof~~ comprising administering to the individual an effective amount of ~~exo-S-mecamylamine or a salt thereof, which is substantially free of exo-R-mecamylamine; and at least one additional agent selected from a tricyclic antidepressant, a monoamine oxidase inhibitor, a selective serotonin reuptake inhibitor, a selective norepinephrine reuptake inhibitor, a serotonin-norepinephrine reuptake inhibitor, a norepinephrine dopamine reuptake inhibitor, or other antidepressant.~~

26. (Currently amended) The method of claim 25, wherein the ~~mood disorder is~~ major depressive disorder ~~[[,]] is single episode major depressive disorder[[,]] or recurrent episode major depressive disorder,~~ hypomanic episode, manic episode, mixed episode, dysthymic disorder, depressive disorder NOS, depressive neurosis, depressive reaction, postpartum depression, premenstrual syndrome, neurotic depression, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder, anxiety disorder, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, social phobia, or depression.

27. (Currently amended) The method of claim 26, wherein the ~~mood disorder~~ major depressive disorder is a refractory disorder.

28. (Cancelled)

29. (Currently amended) The method of claim [[28]] 25, wherein:

(a) the tricyclic antidepressant is doxepin, amitriptyline, amoxapine, clomipramine, desipramine, imipramine, maprotiline, nortriptyline, protriptyline, trimipramine, or a salt thereof;

(b) the monoamine oxidase inhibitor is isocarboxazid, phenelzine, tranylcypromine, or a salt thereof;

(c) the selective serotonin reuptake inhibitor is citalopram, clovoxamine, escitalopram, femoxetine, flesinoxan, fluoxetine, fluvoxamine, paroxetine, sertraline, trazodone, zimeldine, or a salt thereof;

(d) the selective norepinephrine reuptake inhibitor is atomoxetine, ~~venlafaxine, duloxetine~~, or a salt thereof; and

(e) the norepinephrine dopamine reuptake inhibitor is bupropion or a salt thereof; and

(f) the serotonin-norepinephrine reuptake inhibitor is venlafaxine, duloxetine, or a salt thereof.

30. (Previously Presented) The method of claim 25, wherein the exo-S-mecamylamine is exo-S-mecamylamine hydrochloride.

31. (Previously Presented) The method of claim 25, wherein the exo-S-mecamylamine or salt thereof is administered in a daily amount of from about 0.05 mg to about 15 mg; and the at least one additional agent is administered in a daily amount of from about 10 mg to about 80 mg.

32. (Currently amended) The method of claim 25, wherein the exo-S-mecamylamine or salt thereof is administered once or twice daily; and the at least one additional agent is administered once, twice, three, or four times daily.

33. (Previously Presented) The method of claim 25, wherein the exo-S-mecamylamine or salt thereof and the at least one additional agent are administered together or individually.

34. (Currently amended) The method of claim 25, wherein the at least one additional agent is a selective serotonin reuptake inhibitor, citalopram.

35. (Currently amended) The method of claim [[34]] 25, wherein the major depressive disorder ~~mood disorder~~ is refractory major depressive disorder.

36. (Cancelled)

37. (New) The method of claim 25, wherein the exo-S-mecamylamine or salt thereof is administered orally.